AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group

Recruitingn/aAges 18 Years - 85 YearsAllSanten SAS
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to collect safety and performance data on the PRESERFLO™ MicroShunt XI in patients diagnosed with primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥18 mmHg and ≤35 mmHg and/or where glaucoma progression warrants surgery.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Male or female, age 18 to 85 years, inclusive 2. Patient diagnosed with primary open glaucoma where the IOP is not adequately controlled on maximum tolerated medical therapy and has intraocular pressure ≥18 mmHg and ≤35 mmHg while on glaucoma medications 3. Patient willing to comply with study requirements 4. Patient who has signed an approved informed consent form Exclusion Criteria: 1. Angle closure glaucoma 2. Presence of conjunctival scarring, previous incisional ophthalmic surgery involving the conjunctiva or conjunctival pathologies (e.g., thin conjunctiva, pterygium) 3. Active iris neovascularization 4. Active inflammation (e.g., blepharitis, conjunctivitis, scleritis, keratitis, uveitis) 5. Vitreous in the anterior chamber 6. Presence of an anterior chamber intraocular lens (ACIOL) 7. Intraocular silicone oil 8. Need for glaucoma surgery combined with other ocular procedures (e.g., cataract surgery with IOL implantation) or anticipated need for additional ocular surgery during the investigational period 9. Central corneal thickness that is less than 450 microns or greater than 620 microns 10. Previous cilioablative procedure 11. Neovascular glaucoma 12. Uveitic Glaucoma 13. Pseudoexfoliative or pigmentary glaucoma 14. Chronic inflammation 15. Previous incisional ophthalmic surgery within 6 months prior to study 16. Enrolled in this or another study (only one eye can participate in this study) or completed their participation in another study within 30 calendar days of the screening exam 17. Ocular pathology or medical condition for which, in the investigator's judgment, the following factors would either place the patient at increased risk of complications or contraindicate device implantation or interfere with compliance to elements of the Protocol
💊

What it tests

  • Microshunt XI
📍

Where

11 sites
AKH Wien
Vienna, Austria
Glaucoma Clinic, UZ Leuven
Leuven, Belgium
Internationale Innovative Opthalmochirurgie GbR
Düsseldorf, Germany
Universitätsklinikum Tübingen, Department für Augenheilkunde
Tübingen, Germany
Irccs Fondazione G. B. Bietti
Rome, Italy
Policlinico Universitario Molinette
Turin, Italy
Universiteitskliniek voor Oogheelkunde Maastricht
Maastricht, Netherlands
ULS Santa Maria, Lisboa
Lisbon, Portugal

…and 3 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy